Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease

Published: May 08, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics, announced the presentation of data for EBI-005, the lead drug candidate from Eleven’s AMP-Rx product engine, at the Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting. Eleven Biotherapeutics researchers presented preclinical data demonstrating optimal properties of EBI-005 for the treatment of dry eye disease (DED), such as high potency, thermal stability and very low systemic exposure. EBI-005, is the first ever rationally-designed, IL-1 (Interleukin-1) receptor inhibitor protein for topical administration that is optimized for the treatment of DED and other ocular surface inflammatory disorders.

Back to news